Danish leader will face a challenging landscape among competitors ...

Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) investors concerning the Company's possible violations of federal ...

The Law Offices of Frank R. Cruz continues its investigation of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) on behalf of investors concerning the Company's possible violations of ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts for the year amid competition from US copycat weight-loss ...

Shares of Hims & Hers, which has clashed with Novo Nordisk over its sales of compounded glucagon-like peptide inhibitors, rose slightly in the wake of the report, and have more than doubled in value ...

Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...

Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...